BG108427A - 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diaryl pyrimidines as crf1 receptor modulators - Google Patents
2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diaryl pyrimidines as crf1 receptor modulatorsInfo
- Publication number
- BG108427A BG108427A BG108427A BG10842703A BG108427A BG 108427 A BG108427 A BG 108427A BG 108427 A BG108427 A BG 108427A BG 10842703 A BG10842703 A BG 10842703A BG 108427 A BG108427 A BG 108427A
- Authority
- BG
- Bulgaria
- Prior art keywords
- compounds
- disorders
- diarylpyridines
- diarylpyrazines
- receptor modulators
- Prior art date
Links
- 108091005471 CRHR1 Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 108010056643 Corticotropin-Releasing Hormone Receptors Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000004807 localization Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 239000000523 sample Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29748301P | 2001-06-12 | 2001-06-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG108427A true BG108427A (en) | 2005-01-31 |
Family
ID=23146501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG108427A BG108427A (en) | 2001-06-12 | 2003-12-08 | 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diaryl pyrimidines as crf1 receptor modulators |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US6887875B2 (OSRAM) |
| EP (1) | EP1399428A1 (OSRAM) |
| JP (1) | JP2005500286A (OSRAM) |
| AP (1) | AP2003002924A0 (OSRAM) |
| BG (1) | BG108427A (OSRAM) |
| CA (1) | CA2450262A1 (OSRAM) |
| EC (1) | ECSP034898A (OSRAM) |
| HR (1) | HRP20031096A2 (OSRAM) |
| HU (1) | HUP0400179A3 (OSRAM) |
| IL (1) | IL159058A0 (OSRAM) |
| IS (1) | IS7060A (OSRAM) |
| MX (1) | MXPA03011391A (OSRAM) |
| PL (1) | PL367476A1 (OSRAM) |
| RU (1) | RU2003136151A (OSRAM) |
| TN (1) | TNSN03133A1 (OSRAM) |
| WO (1) | WO2002100838A1 (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL146531A0 (en) * | 2000-03-16 | 2002-07-25 | Neurogen Corp | 5-substituted arylpyrimidines |
| US6964965B2 (en) | 2002-04-26 | 2005-11-15 | Pharmacia & Upjohn | Substituted pyrazine derivatives |
| ATE325115T1 (de) | 2002-08-19 | 2006-06-15 | Glaxo Group Ltd | Pyrimidinderivate als selektive cox-2-inhibitoren |
| GB0221443D0 (en) | 2002-09-16 | 2002-10-23 | Glaxo Group Ltd | Pyridine derivates |
| GB0225548D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Compounds |
| AU2003278542A1 (en) * | 2002-11-21 | 2004-06-15 | Pharmacia & Upjohn Company Llc | Pyrazine compounds as crf modulators |
| JP2007512275A (ja) | 2003-11-24 | 2007-05-17 | エフ．ホフマン−ラ ロシュ アーゲー | ピラゾリルおよびイミダゾリルピリミジン |
| US20080132522A1 (en) * | 2004-07-14 | 2008-06-05 | Basf Aktiengesellschaft | 2-Substituted Pyrimidines, Method for Their Production and Their Use for Controlling Pathogenic Fungi |
| TW200637556A (en) * | 2005-01-31 | 2006-11-01 | Basf Ag | Substituted 5-phenyl pyrimidines I in therapy |
| KR20080040692A (ko) * | 2005-08-02 | 2008-05-08 | 렉시컨 파마슈티컬스 인코퍼레이티드 | 단백질 키나제 억제제로서의 2-아미노아릴 피리딘 |
| TW200908984A (en) * | 2007-08-07 | 2009-03-01 | Piramal Life Sciences Ltd | Pyridyl derivatives, their preparation and use |
| US7932256B2 (en) * | 2008-07-31 | 2011-04-26 | Bristol-Myers Squibb Company | (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity |
| WO2011051478A1 (en) * | 2009-10-30 | 2011-05-05 | Domain Therapeutics | Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
| US9357781B2 (en) | 2013-05-03 | 2016-06-07 | Inscent, Inc. | Honeybee repellents and uses thereof |
| US9351494B2 (en) | 2013-05-03 | 2016-05-31 | Inscent, Inc. | Honeybee repellents and uses thereof |
| CN105254576A (zh) * | 2014-02-26 | 2016-01-20 | 中国科学院长春应用化学研究所 | 一种谷氨酸二酮哌嗪的制备方法 |
| KR102708681B1 (ko) | 2018-02-13 | 2024-09-26 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| CN118221646A (zh) | 2018-07-13 | 2024-06-21 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| JP2022074173A (ja) * | 2019-03-18 | 2022-05-18 | 住友化学株式会社 | ２，５－ジクロロピラジンの製造方法 |
| CN112142716B (zh) * | 2020-10-29 | 2021-08-31 | 山东新时代药业有限公司 | 一种5元杂芳基取代的吡嗪衍生物及其应用 |
| CN113429354A (zh) * | 2021-07-22 | 2021-09-24 | 广东嘉博制药有限公司 | 一种盐酸甲氧明聚合物杂质及其制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1463813A (fr) * | 1964-02-26 | 1966-07-22 | Ciba Geigy | Nouvelles amino-phénylcétones et procédé pour leur préparation |
| US3660404A (en) * | 1969-02-24 | 1972-05-02 | Du Pont | U.v.-absorbing ortho-hydroxyphenyl substituted bipyrimidyls |
| DE2064380C3 (de) * | 1970-12-30 | 1981-01-22 | Hoechst Ag, 6000 Frankfurt | Lichtempfindliches Gemisch |
| JPS625970A (ja) | 1985-03-15 | 1987-01-12 | Terumo Corp | ピラジン誘導体およびこれを含有する血小板凝集抑制剤 |
| DE68926635T2 (de) * | 1988-04-25 | 1997-01-02 | Dainippon Ink & Chemicals | 2,5-Disubstituierte Pyrazin-Derivate, Pyrimidin-Derivate und sie enthaltende Flüssigkristalle |
| JPH02209873A (ja) * | 1989-02-08 | 1990-08-21 | Dainippon Ink & Chem Inc | 光学活性２，５―ジ置換ピリミジン誘導体 |
| JP2770385B2 (ja) * | 1989-03-16 | 1998-07-02 | セイコーエプソン株式会社 | ピリミジン誘導体 |
| WO1995010506A1 (en) * | 1993-10-12 | 1995-04-20 | The Du Pont Merck Pharmaceutical Company | 1n-alkyl-n-arylpyrimidinamines and derivatives thereof |
| JPH0948760A (ja) * | 1995-08-03 | 1997-02-18 | Dainippon Ink & Chem Inc | ピリミジン化合物 |
| JP4044175B2 (ja) * | 1996-07-26 | 2008-02-06 | 株式会社半導体エネルギー研究所 | 光学活性化合物及び該化合物を含有する反強誘電性液晶組成物 |
| US6686486B1 (en) * | 1997-05-07 | 2004-02-03 | Padma Marwah | Process for effecting allylic oxidation |
| SE9702651D0 (sv) * | 1997-07-09 | 1997-07-09 | Astra Pharma Prod | Novel compounds |
| WO1999038829A1 (en) * | 1998-01-28 | 1999-08-05 | Shionogi & Co., Ltd. | Novel tricyclic compound |
| CO5210940A1 (es) * | 1999-05-04 | 2002-10-30 | Novartis Ag | Compuestos plaguicidas derivados de pirimidina y composiciones que los contienen |
| NZ520484A (en) * | 2000-02-16 | 2005-03-24 | Neurogen Corp | Substituted arylpyrazines that are modulators of CRF (corticotropin releasing factor) receptor and methods of treatment using them |
-
2002
- 2002-05-22 HR HR20031096A patent/HRP20031096A2/xx not_active Application Discontinuation
- 2002-05-22 JP JP2003503606A patent/JP2005500286A/ja active Pending
- 2002-05-22 RU RU2003136151/04A patent/RU2003136151A/ru not_active Application Discontinuation
- 2002-05-22 EP EP02737167A patent/EP1399428A1/en not_active Withdrawn
- 2002-05-22 CA CA002450262A patent/CA2450262A1/en not_active Abandoned
- 2002-05-22 HU HU0400179A patent/HUP0400179A3/hu unknown
- 2002-05-22 IL IL15905802A patent/IL159058A0/xx unknown
- 2002-05-22 WO PCT/US2002/016518 patent/WO2002100838A1/en not_active Ceased
- 2002-05-22 AP APAP/P/2003/002924A patent/AP2003002924A0/en unknown
- 2002-05-22 US US10/154,482 patent/US6887875B2/en not_active Expired - Fee Related
- 2002-05-22 PL PL02367476A patent/PL367476A1/xx not_active Application Discontinuation
- 2002-05-22 MX MXPA03011391A patent/MXPA03011391A/es unknown
-
2003
- 2003-07-08 TN TNPCT/US2002/016518A patent/TNSN03133A1/en unknown
- 2003-11-28 IS IS7060A patent/IS7060A/is unknown
- 2003-12-08 BG BG108427A patent/BG108427A/xx unknown
- 2003-12-12 EC EC2003004898A patent/ECSP034898A/es unknown
-
2005
- 2005-04-04 US US11/098,885 patent/US20050176721A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0400179A2 (hu) | 2004-08-30 |
| US6887875B2 (en) | 2005-05-03 |
| IS7060A (is) | 2003-11-28 |
| RU2003136151A (ru) | 2005-05-20 |
| CA2450262A1 (en) | 2002-12-19 |
| MXPA03011391A (es) | 2004-07-01 |
| TNSN03133A1 (en) | 2005-12-23 |
| JP2005500286A (ja) | 2005-01-06 |
| US20050176721A1 (en) | 2005-08-11 |
| PL367476A1 (en) | 2005-02-21 |
| US20030119844A1 (en) | 2003-06-26 |
| AP2003002924A0 (en) | 2003-12-31 |
| IL159058A0 (en) | 2004-05-12 |
| WO2002100838A1 (en) | 2002-12-19 |
| EP1399428A1 (en) | 2004-03-24 |
| HUP0400179A3 (en) | 2004-10-28 |
| HRP20031096A2 (en) | 2005-08-31 |
| ECSP034898A (es) | 2004-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG108427A (en) | 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diaryl pyrimidines as crf1 receptor modulators | |
| WO2005028480A3 (en) | 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds | |
| TNSN03119A1 (en) | 5-substituted-2-arylpyridines as crf1 modulators | |
| EA200600372A1 (ru) | Конденсированные с гетероарилом пиридины, пиразины и пиримидины в качестве лигандов рецептора кортикотропин-рилизинг-фактора (crf 1) | |
| WO2005115399A3 (en) | Imidazopyrazines, imidazopyridines, ans imidazopyrimidines as crf1 receptor ligands | |
| NO20021357D0 (no) | Amino-substituerte pyrazolo[1,5-a]-1,5-pyrimidiner og pyrazolo[1,5-a]-1,3,5-triaziner | |
| HUP0003386A3 (en) | Use of crf antagonists for the preparation of pharmaceutical compositions treating depression, cardiovascular diseases | |
| PL367814A1 (en) | 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity | |
| BG106506A (en) | ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO[1,5,-a)-1,5-PYRIMIDINES AND PARAZOLO[1,5-a)-1,3,5-TRIAZINES | |
| IL150085A0 (en) | New-p2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases | |
| WO2002006242A3 (en) | 5-substituted 2-aryl-4-pyrimidinones | |
| MY129328A (en) | Triamide-substituted heterobicyclic compounds | |
| MY137535A (en) | New pyrrolidinium derivatives | |
| HUP0303651A3 (en) | N-(2-arylethyl)benzylamines as antagonists of the 5-ht6 receptor and pharmaceutical compositions containing them | |
| WO2003028641A3 (en) | Mch receptor antagonists | |
| JO2359B1 (en) | Benzathene derivatives as agents for modulation of GABA A receptor | |
| MXPA05010137A (es) | Derivados de tetrahidroisoquinolil acetamida para usarse como antagonistas del receptor de orexina. | |
| MXPA04002982A (es) | Derivados de pirrolidinona. | |
| WO2005030188A3 (en) | Phenyl-piperazine derivatives as modulators of muscarinic receptors | |
| YU80902A (sh) | Novi indolin-2-on derivati, njihovo dobijanje i farmaceuski oblici koji ih sadrže | |
| WO2007133756A3 (en) | Crf1 receptor ligands comprising heteroaryl fused bicycles | |
| TW200621244A (en) | Modulators of muscarinic receptors | |
| WO2006058294A3 (en) | Modulators of muscarinic receptors | |
| MXPA05007771A (es) | Procedimientos de tratamiento del dolor articular o para mejorar el sueno usando un agonista/antagonista de estrogeno. | |
| WO2001068614A3 (en) | 5-substituted arylpyrimidines |